The Invesco Agriculture Commodity Strategy No K-1 ETF has given up its wartime gains, reflecting a return to normal pricing for agricultural futures related to the 2027 harvest. Despite high volatility, the ETF's long-term returns remain negligible, with a very low Sharpe Ratio since 1988. Current market conditions show the ETF as deeply oversold, but improved weather and stabilized fertilizer shipments reduce near-term upside potential. The analyst recommends focusing on targeted commodity funds with more exposure to hard commodities for better inflation protection and superior risk-adjusted returns compared to broad agricultural ETFs like this one.
The Invesco Agriculture Commodity Strategy No K-1 ETF is the subject, with Pluang market data providing context. For readers following US stocks on Pluang, as of Nov 13, 2026 15:11 WIB, 69 of 150 stocks rose while 79 fell. Notable movers include XPEV at USD 9.25 with a 1-day change of -2.22%, BABA at USD 92.33 down 2.15%, and HOOD at USD 79.61 down 2.14%.
The Philippines solar energy market is projected to grow from 5.43 GW in 2026 to 23.35 GW by 2032, with a CAGR of 27.46%. Growth is fueled by declining costs of solar panels and installation, government-backed renewable energy auctions, and increasin...
Equinor ASA shares will trade ex-dividend on the Oslo Stock Exchange starting November 13, 2026, for the second quarter of 2026. The declared dividend amount is $0.39 per share, payable in USD. This means investors buying shares from this date will n...
China Eastern Airlines signed 23 procurement agreements worth $540 million with 15 suppliers from eight countries at the 9th China International Import Expo in Shanghai. The deals cover aircraft engines, aviation materials, jet fuel, and in-flight ca...
Eramet announced a €500 million share capital increase through a rights issue, offering 6 new shares for every 5 existing shares at €14.49 each. The proceeds will be used to reduce the company's debt and strengthen its balance sheet as part of a prev...
Pasithea Therapeutics announced positive Phase 1/1b results for PAS-004, showing significant reductions in cutaneous neurofibromas (cNF) size by up to 71% with continued treatment and early activity in plexiform neurofibromas (PN). The drug demonstra...
